Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Importantly, we believe our solid financial position will fuel continued growth and evolution of our RADR AI platform, accelerate the development of our portfolio of targeted oncology drug candidates and allow us to introduce additional targeted programs and collaboration opportunities in a capital-efficient manner |
| At the same time, our CFO David Margrave will cover shortly, we have a very strong cash position, approximately $41.3 million in cash, cash equivalents, and marketable securities |
| We think year over year we'll continue to make improvements and continue to refine and make our process more efficient, more precise and potentially even more powerful |
| Our collective efforts and dedication have fostered a transformational shift for our company, setting us on an exciting trajectory towards the future, where we're improving the lives of cancer patients with effective and more economically generated treatment options |
| We're very excited about what the future holds for us |
| And we believe we'll have the potential to be another very positive impact on our investors as we monetize this unique asset, the patents and, of course, the insights |
| We believe that companies that harness these capabilities in biotech and more appropriately really the tech bio industry will become long term leaders that create massive value for patients, for investors and for our industry |
| We filed 11 patent applications last year across our drug candidates and our AI platform and we continue to show very strong focused fiscal discipline |
| Together, we're really lighting the way toward a brighter and better future in oncology and solving real-world problems with proprietary high-value AI solutions that enable rapid development of genomically targeted therapies |
| Our R&D expenses continue to exceed our G&A expenses by a strong margin, reflecting our focus on advancing our product candidates and pipeline |
| Lantern's leadership in the innovative use of AI and machine learning to transform costs and timelines in the development of precision oncology therapies should yield significant returns for investors and patients as our industry matures and adopts an AI-centric and data-first approach to drug development |
| The drug has some very good history in terms of its ability to be a proven mechanistic manner in which you can kill GBM cells, which is an alkylating agent |
| They've made significant strides over the past quarter and throughout 2023 across all our programs and also with our AI platform radar |
| And we've been successful in moving towards regulatory allowance for commencing our trial in Japan, Taiwan and South Korea where the incidence of non-small cell lung cancer among never smokers is nearly two and a half to three times that here in the US |
| This transformation has the promise to not only make medicines faster, cheaper and with increased precision for patients but also to help change the direction of R&D productivity and output in the pharma industry |
| So I think it was a very unique opportunity |
| But in particular in that collaboration we found that we had excellent control over the cysteine engineered proteins and that allowed us to have great control of the bio-conjugation process and we also saw very high potency in the picomolar range across six solid tumors, many of them with huge clinical need |
| As we continue to accelerate the pace at which we're developing and validating insights that can lead to meaningful drug assets that we can partner, license, sell in the future, we believe that we're very well positioned to partner these drug assets out to larger companies |
| In the past three years, we have successfully developed and launched 11 additional programs, a testament to the agility, efficiency and groundbreaking nature of our approach |
| And we believe that we'll have over eight of these modules and all will help us advance and improve the speed, the precision and the efficiency of RADR's drug development kind of co-piloting capabilities |
| So it is exciting |
| Marc Chamberlain, during the fourth quarter, and he's made excellent progress on advancing our clinical trial design in both adult and pediatric CNS cancers, and we expect to launch the initial adult trial during the second half of this year |
| We believe this is a great year to keep on communications with all of our interested parties very high |
| As we mentioned earlier in the call, one of the areas that we're very excited about is Starlight Therapeutics |
| Our leadership and the innovative use of AI and machine learning to transform costs and timelines has allowed us to bring three molecules to market with teams, costs and efficiency that is only beginning to make a massive impact |
| Our team and many clinicians are particularly excited about and interested in the programs for our first in human drug candidates, LP-184 and LP-284, also our unique drug LP-300, which we in-licensed and rescued is aimed at never smokers, who've been impacted by non-small cell lung cancer but have failed other treatment options |
| We were able to take our cryptophycin antibody drug conjugate, and advanced it not only in proven synthesis and bioconjugation, but developed a preclinical proof of concept that it worked really well in an area of high unmet need, which is moderate HER2 expression |
| We're very excited about this molecule, and we'll have data this year on the Phase I trial |
| So we're in a good drug class |
| So you can see why we're particularly excited about this molecule, why we spent a lot of time understanding its molecular profile, understanding the triggers of patient response, understanding the indications where it'll be most sensitive and then also developing patents around combining this unique drug with other therapies |
| Statement |
|---|
| In fact, in a recent study published by Drug Discovery Today, it was reported that nearly half of the 16 largest pharma companies had negative R&D productivity over the last 18 to 20 years, with Big Pharma collectively spending close to $3 billion per drug approval |
| Lung cancer among never smokers is a growing problem not only in the US but globally |
| These are startling figures and they serve as a stark reminder that the traditional model of Big Pharma R&D is not a sustainable or effective strategy and it is not the right approach to improve drug pricing or drug availability |
| A number of factors could cause actual results to differ materially from those indicated by forward-looking statements, including results of clinical trials and the impact of competition |
| We recorded a net loss of approximately $4.2 million for the fourth quarter of 2023 or $0.39 per share compared to a net loss of approximately $3.4 million or $0.31 per share for the fourth quarter of 2022 |
| Our loss from operations in the 2023 calendar year was partially offset by interest income and other income net, totaling approximately $1.9 million |
| Our general and administrative expenses were approximately $1.3 million for the fourth quarter of 2023, down somewhat from approximately $1.6 million in the prior year period |
Please consider a small donation if you think this website provides you with relevant information